|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
03347 TIGERMED
Nominal 
32.350 -1.650 (-4.853%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 7,384,039 | 4.214% | 7,085,471 | 5,213,538 | 3,192,279 | 2,803,309 |
| Cost of Sales | (4,563,378) | 6.124% | (4,300,027) | (2,965,420) | (1,688,946) | (1,511,409) |
| Gross Profit | 2,820,661 | 1.264% | 2,785,444 | 2,248,118 | 1,503,333 | 1,291,900 |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (68,098) | 177.103% | (24,575) | (24,426) | 10,075 | (21,186) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | (3,567) | -- | |
| Share of Results of Asso. & JCEs | 105,183 | 164.525% | 39,763 | 14,348 | (3,508) | (9,768) | |
| Profit / (Loss) before Taxation | 2,490,191 | -4.036% | 2,594,912 | 3,689,502 | 2,220,262 | 1,088,772 | |
| Taxation | (338,606) | 7.956% | (313,652) | (292,864) | (189,707) | (113,839) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (125,078) | -52.832% | (265,174) | (517,539) | (279,227) | (133,686) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 2,026,507 | 0.517% | 2,016,086 | 2,879,099 | 1,751,328 | 841,247 | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (110,927) | -23.630% | (145,249) | (234,139) | (63,317) | 15,409 |
| Depreciation & Amortisation | 339,024 | 19.021% | 284,844 | 196,762 | 150,256 | 104,202 |
| Directors' Emoluments | 8,929 | 13.442% | 7,871 | 3,487 | 3,395 | 2,801 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | 234.000 | 0.429% | 233.000 | 332.000 | 220.000 | 113.000 |
| DPS (cts) | 56.800 | -- | 55.000 | 50.000 | 30.000 | -- |
| Dividend Payout Ratio (%) | 24.274% | -- | 23.605% | 15.060% | 13.636% | -- |
| Cash flow per share ($) | 1.077 | -- | 1.311 | 1.343 | 1.125 | 0.725 |
| NBV per share ($) | 24.150 | -- | 22.499 | 20.844 | 18.514 | -- |
| Remarks: | Real time quote last updated: 22/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 492,849 |
| %Change | -64.501% |
| EPS / (LPS) | RMB 0.570 |
| NBV Per Share (¥) | RMB 24.007 |